Skip to content
Menu

JP Morgan Maintains Overweight on Praxis Precision Medicine, Raises Price Target to $725

Benzinga Newsdesk 2 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

JP Morgan analyst Tessa Romero maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Overweight and raises the price target from $700 to $725.

JP Morgan analyst Tessa Romero maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Overweight and raises the price target from $700 to $725.

Read at benzinga.com